Devyser Diagnostics AB
The answer first
Does Devyser Diagnostics beat the market?
No, Devyser Diagnostics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 38% of Nordic stocks
- Quality89
- Value24
- Trend23
No. 85 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Devyser Diagnostics keeps must grow about 9% a year for 10 years.
Max for seven days
Follow Devyser Diagnostics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Devyser Diagnostics
Your first answer is free, no account needed.
Do you own Devyser Diagnostics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Devyser Diagnostics and a few more. Free, no card.
Super Stock+45.9%In short
- Devyser Diagnostics has fallen 42.4% over the past year, including dividends.
- Overall, Devyser Diagnostics ranks better than 38% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 68.5%. The price is 60.0% below its peak now.
What do analysts think of Devyser Diagnostics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 38% of Nordic stocks.
No. 85 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 35 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.15
- Asset turnoverSales divided by everything the company owns0.51
- Return on equityProfit divided by equity+6.5%
- Cash conversionOperating cash flow divided by profit2.29
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 88 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity2.7
- P/SPrice divided by sales4.1
- P/EPrice divided by earnings41.2
- P/CFPrice divided by operating cash flow18.2
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 117 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+3.3%
- 6 months−34.6%
- 9 months−34.9%
- 12 months−42.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Devyser Diagnostics
8 funds we follow own Devyser Diagnostics. The share is how much of the fund the stock makes up.
- Sweden8
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo3.9%
- TIN Småbolag ASweden · TIN2.5%
- Case Gaia MicrocapSweden · Case1.4%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest1.3%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest1.3%
- Aktiespararna Småbolag EdgeSweden · Aktiespararna1.2%
- PLUS Hälsovård Sverige IndexSweden · PLUS0.4%
- Handelsbanken Hälsovård Tema (A1 SEK)Sweden · Handelsbanken0.2%
From the funds' latest known holdings.
About Devyser Diagnostics
Devyser Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 110 employees.
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.


See the full analysis of Devyser Diagnostics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card